Display options
Cite
Bewley A, Fowler J, Schöfer H, et al. Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis. Dermatol Ther (Heidelb). 2016;6(2):237-47doi: 10.1007/s13555-016-0106-9.
Bewley, A., Fowler, J., Schöfer, H., Kerrouche, N., & Rives, V. (2016). Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis. Dermatology and therapy, 6(2), 237-47. https://doi.org/10.1007/s13555-016-0106-9
Bewley, Anthony, et al. "Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis." Dermatology and therapy vol. 6,2 (2016): 237-47. doi: https://doi.org/10.1007/s13555-016-0106-9
Bewley A, Fowler J, Schöfer H, Kerrouche N, Rives V. Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis. Dermatol Ther (Heidelb). 2016 Jun;6(2):237-47. doi: 10.1007/s13555-016-0106-9. Epub 2016 Mar 16. PMID: 26983751; PMCID: PMC4906100.
Copy Download .nbib Format: NLM
Share it on

Dermatol Ther (Heidelb). 2016 Jun;6(2):237-47. doi: 10.1007/s13555-016-0106-9. Epub 2016 Mar 16.

Erythema of Rosacea Impairs Health-Related Quality of Life: Results of a Meta-analysis.

Dermatology and therapy

Anthony Bewley, Joseph Fowler, Helmut Schöfer, Nabil Kerrouche, Vincent Rives

Affiliations

  1. Whipps Cross University Hospital and the Royal London Hospital, London, UK. [email protected].
  2. University of Louisville, Louisville, KY, USA.
  3. Universitätshautklinik, Klinikum der Goethe Universität, Frankfurt am Main, Germany.
  4. Galderma R&D, Sophia Antipolis, France.
  5. Galderma International, Paris, France.

PMID: 26983751 PMCID: PMC4906100 DOI: 10.1007/s13555-016-0106-9

Abstract

INTRODUCTION: The central diagnostic feature of rosacea is diffuse central-facial erythema. The objective was to summarize published and unpublished health-related quality of life (HRQoL) data from seven previous studies in rosacea patients.

METHODS: A meta-analysis was performed on baseline HRQoL data of subjects with erythema of rosacea from five randomized controlled trials, one open-label safety study and one epidemiological study. The data from four questionnaires were analyzed, including the Euro QoL 5-dimension (EQ5D) generic questionnaire, the Dermatology Life Quality Index (DLQI) dermatology-specific quality of life instrument, the Productivity and Social Life Questionnaire and the Facial Redness Questionnaire.

RESULTS: The global EQ5D index score was 0.859 and the domains of pain/discomfort (31.5% moderate or extreme pain) and anxiety/depression (26.4% moderate or extreme) were most affected. Worse scores were observed with erythema of rosacea in the absence of inflammatory lesions (EQ5D score of 0.832 for no lesions vs 0.919 for subjects with ≥1 lesion). Almost half (43%) the subjects had at least moderately impaired HRQoL, including 19.8% with a DLQI total score of ≥11 indicating severely impaired HRQoL; symptoms/feelings was the most affected domain. Subjects with a patient self-assessment (PSA) of severe erythema of rosacea had a worse mean DLQI score than moderate PSA subjects (8.6 vs 6.0). Work life and social life were affected, especially in subjects with severe PSA (62% with social life at least somewhat affected).

CONCLUSION: Erythema of rosacea causes a marked decrease in HRQoL in most patients, especially those with self-perceived severe erythema and without inflammatory lesions, and should thus be considered as an important medical problem requiring medical intervention.

FUNDING: Galderma UK.

Keywords: DLQI; EQ5D; Erythema; Mirvaso; Quality of life; Redness; Rosacea; Self-esteem

References

  1. Clin Exp Dermatol. 1994 May;19(3):210-6 - PubMed
  2. BMJ. 2001 May 26;322(7297):1297-300 - PubMed
  3. J Eur Acad Dermatol Venereol. 2015 Dec;29(12 ):2405-10 - PubMed
  4. Am Health Drug Benefits. 2013 Jul;6(6):348-54 - PubMed
  5. J Eur Acad Dermatol Venereol. 2015 Mar;29(3):474-81 - PubMed
  6. Dermatology. 2007;215(4):315-9 - PubMed
  7. Patient Relat Outcome Meas. 2015 Jul 07;6:167-77 - PubMed
  8. Br J Dermatol. 2010 Oct;163(4):719-25 - PubMed
  9. J Drugs Dermatol. 2013 Jun 1;12(6):650-6 - PubMed
  10. Dermatology. 2007;215(4):273-6 - PubMed
  11. J Drugs Dermatol. 2014 Jan;13(1):56-61 - PubMed
  12. Dermatol Ther (Heidelb). 2015 Sep;5(3):171-81 - PubMed
  13. J Am Acad Dermatol. 2010 Jun;62(6):1069-71 - PubMed
  14. Dermatol Clin. 2012 Apr;30(2):205-8, xiii - PubMed
  15. Acta Derm Venereol. 2015 Apr;95(4):395-400 - PubMed
  16. Cutis. 2005 Mar;75(3):181-7 - PubMed
  17. J Am Acad Dermatol. 2002 Apr;46(4):584-7 - PubMed
  18. Cochrane Database Syst Rev. 2015 Apr 28;(4):CD003262 - PubMed
  19. J Dermatol Surg Oncol. 1991 Jun;17(6):522-5 - PubMed
  20. J Investig Dermatol Symp Proc. 2004 Mar;9(2):169-80 - PubMed
  21. J Am Acad Dermatol. 2014 Nov;71(5):973-80 - PubMed
  22. Dermatol Ther (Heidelb). 2015 Jun;5(2):117-27 - PubMed
  23. Br J Dermatol. 2012 Mar;166(3):633-41 - PubMed
  24. J Eur Acad Dermatol Venereol. 2016 Mar;30(3):428-34 - PubMed
  25. J Am Acad Dermatol. 2004 Oct;51(4):592-9 - PubMed
  26. J Cosmet Laser Ther. 2009 Sep;11(3):139-41 - PubMed

Publication Types